Novo Nordisk A/S (NVO)
| Market Cap | 260.80B |
| Revenue (ttm) | 49.11B |
| Net Income (ttm) | 17.49B |
| Shares Out | 4.44B |
| EPS (ttm) | 3.93 |
| PE Ratio | 14.92 |
| Forward PE | 16.15 |
| Dividend | $1.23 (2.16%) |
| Ex-Dividend Date | Aug 18, 2025 |
| Volume | 15,046,654 |
| Open | 58.60 |
| Previous Close | 58.68 |
| Day's Range | 56.79 - 58.80 |
| 52-Week Range | 45.05 - 120.56 |
| Beta | 0.33 |
| Analysts | Buy |
| Price Target | 82.20 (+44.39%) |
| Earnings Date | Nov 5, 2025 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for NVO stock is "Buy." The 12-month stock price target is $82.2, which is an increase of 44.39% from the latest price.
News
Novo Nordisk halts work on cell therapy for diabetes to cut costs, Bloomberg News reports
Novo Nordisk has cut its cell therapy division, which has been trying to find a cure for type 1 diabetes, Bloomberg News reported on Friday, citing a statement.
Novo Nordisk A/S (NVO) M&A Call Transcript
Novo Nordisk A/S (NVO) M&A Call October 9, 2025 8:00 AM EDT Company Participants Jacob Martin Rode - Head of Investor Relations Maziar Doustdar - President, CEO & Member of the Management Board Ludovi...
Novo Nordisk to acquire Akero Therapeutics for its experimental liver disease drug
Novo Nordisk said on Thursday it would buy U.S.-based Akero Therapeutics for up to $5.2 billion to add its promising experimental liver disease drug, in the first major deal by the Danish drugmaker's ...
Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion
Novo Nordisk A/S (NYSE:NVO) agreed on Thursday to acquire Akero Therapeutics, Inc. (NASDAQ:AKRO) focused on metabolic diseases.
Akero Therapeutics soars after Novo Nordisk set for $5.2B cash acquisition
Novo Nordisk said on Thursday it would acquire Akero Therapeutics for up to $5.2 billion in cash, marking a significant push into treatments for fatty liver disease as the Danish drugmaker seeks to br...
Akero Therapeutics Stock Soars on Novo Nordisk Deal.
Novo said it would buy Akero for $54 a share in cash and an additional $6 if it gets U.S. approval of Efruxifermin - it's treatment for fatty liver disease.
Novo Nordisk is paying up to $5.2 billion for a San Francisco biotech working on liver disease
Novo Nordisk, the Danish drugmaker behind Ozempic and other weight-loss drugs, said it's paying up to $5.2 billion to buy Akero Therapeutics, a biotech with a drug in a late-stage trial to treat a fat...
Novo Nordisk To Buy Akero Therapeutics for $4.7 Billion
Novo said the acquisition of would contribute to its strategy to develop medicines for people living with diabetes, obesity and their associated comorbidities.
Novo Nordisk to buy Akero for up to $5.2 billion as new CEO bets on liver drug candidate
Novo Nordisk said on Thursday it would buy U.S.-based Akero Therapeutics for up to $5.2 billion to gain access to a promising liver disease drug candidate, in the first major deal by the Danish drugma...
Novo Nordisk buys Akero Therapeutics in the US
Danish drugmaker Novo Nordisk said on Thursday it had agreed to buy United States based Akero Therapeutics, a clinical-stage company developing innovative treatments for patients with serious metaboli...
Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion
Shareholders to Receive $54 Per Share in Cash and CVR of $6 Per Share Advances Akero's Mission of Bringing Novel Therapies to Patients with High Unmet Medical Needs SOUTH SAN FRANCISCO, Calif., Oct. ...
Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio
Bagsværd, Denmark, 9 October, 2025 – Novo Nordisk today announced that it has entered into a definitive agreement to acquire Akero Therapeutics, Inc. (Akero), a publicly held clinical-stage company de...
Final Trade: FCX, NOVO, DE, ZETA
The final trades of the day with the Fast Money traders.
Wall Street Breakfast Podcast: Deals Don't Wait 'Til November
Amazon (AMZN) launches Prime Big Deal Days, kicking off early holiday shopping with exclusive offers and increased competition from Target and Walmart. Novo Nordisk (NVO) cuts dozens of production job...
Novo Nordisk: Oral Wegovy Nears FDA Decision As GLP-1 Momentum Builds
Novo Nordisk is well-positioned in the obesity drug market, with strong financials and anticipation for its oral Wegovy pill. NVO's first-half 2025 results showed robust growth, driven by obesity fran...
Exclusive: Novo Nordisk cuts hit production line jobs at key US plant, posts show
Wegovy-maker Novo Nordisk has laid off dozens of employees at the largest U.S. manufacturing site for its blockbuster obesity and diabetes drugs, a Reuters review of LinkedIn posts showed, a signal of...
US court rejects Novo Nordisk's challenge to Medicare drug pricing plan
A federal appeals court on Monday rejected Novo Nordisk's challenge to the U.S. government's program that gives its Medicare health insurance plan the power to negotiate lower drug prices, the latest ...
Novo Nordisk: CagriSema Sets Potential Obesity Drug Development Comeback
Downgrading Novo Nordisk from a "Strong Buy" rating to a "Buy" rating, whereby it may or may not be able to overcome competition in the obesity drug development space. Company faces competition from E...
"Exciting Race" Between LLY & NVO, Tariffs Remain Long-Term Overhang
Lee Brown sees lots of potential in the weight loss drug space, noting Eli Lilly (LLY) and Novo Nordisk (NVO) as the two companies he expects to lead. He points to "incredible" discounts and expanded ...
Novo Nordisk: The Bottom Is In
NVO trades at a rare dislocation with a forward P/E ~15% below sector and EPS growth ~66% above, primed for the 2026 healthcare re-rating. Its semaglutide engine (Wegovy growth, CagriSema pipeline, hi...
Pharmaceutical Stocks: Valuations And Pipelines Are Only Beginning To Be Appreciated
Drug stocks are poised to outperform in 2025, driven by conservative valuations and a research renaissance in key therapeutic areas. US healthcare spending growth and transformative GLP-1 therapies, e...
Novo plans online launch for obesity pill once approved, Bloomberg News reports
Danish drugmaker Novo Nordisk said it plans to make its new obesity pill available through telehealth platforms like Ro and WeightWatchers once it gets U.S. approval, Bloomberg News reported on Friday...
Novo Nordisk Is Primed For A Post-Earnings Recovery (Earnings Preview)
Novo Nordisk's Q2 2025 results showed resilient revenue growth, but profit guidance was cut due to U.S. competition, compounded drugs, and currency headwinds. I see the upcoming Q3 earnings and Alzhei...
Buy Novo Nordisk Stock as Health Names Return to Favor, Analyst Says
HSBC made the call as it listed the pharma stocks it sees as best positioned to play a recovery in the sector.
Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say
Novo Nordisk's and Eli Lilly's blockbuster weight-loss drugs should be the first medicines doctors reach for to treat obesity and its complications, a major European medical association advised on Thu...